Introduction
Hematopoietic SCT has been an approved treatment for hematological diseases (for example, leukemia, lymphoma and aplastic anemia), certain solid organ tumors, immunodeficiencies, metabolic diseases, among other disorders. However, SCT can cause many complications, such as GVHD, opportunistic infections and graft failure. Although the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) also seems to be one of these complications, there are only few case reports available on SIADH following SCT, 1,2 including our previous report. 3 Therefore, SIADH following SCT has had its importance underestimated.
In our previous report, 3 severe hyponatremia of less than 125 mmol/l was a complication in 27 (19.3%) of the 140 SCT patients, and 16 (56.9%) of them were diagnosed with SIADH. Moreover, multivariate analysis revealed that alternative donor and recipient below the age of 4 years were the only independent predictors of SIADH. However, the mechanism causing SIADH following SCT and the clinical characteristics are still poorly understood. Thus, in this report, we analyzed detailed data on a larger number of patients with SIADH following SCT.
Patients and methods
This study comprised 197 consecutive pediatric patients (126 boys and 71 girls) who received SCT for malignant (149 patients) or non-malignant disease (48 patients) at the Department of Pediatrics, Hokkaido University Hospital between February 1988 and March 2007. Of these patients, 164 received allogeneic transplantation and the remaining 33 patients received autologous transplantation. As prophylaxis for GVHD, almost all patients receiving BMT/ PBSCT received CsA or tacrolimus (FK506) with MTX, whereas almost all patients undergoing cord blood SCT (CBSCT) received CsA with methylprednisolone. CsA and FK506 doses were appropriately adjusted to maintain trough levels of 150-200 ng/ml and 10-20 ng/ml, respectively. All patients received antifungal prophylaxis with amphotericin B or micafungin, antiherpes simplex virus prophylaxis with acyclovir and gut sterilization with polymixin B. Moreover, i.v. immunoglobulin and G-CSF were administered to all patients during the peritransplant period. Transplant characteristics of all patients are summarized in Table 1 .
Serum sodium levels were measured in every patient by a routine automated analyzer every morning until 40 days after SCT and two to three times a week afterwards. We defined hyponatremia as a serum sodium level of less than 125 mmol/l on two consecutive days because serum sodium levels transiently between 125 and 135 mmol/l may not be clinically important. SIADH was diagnosed using the approach reported by Bartter and Schwartz. 4 Diagnosis requires the presence of all of the following criteria: (1) hyponatremia with hypotonicity of plasma; (2) urine osmolality in excess of plasma osmolality; (3) increased renal sodium excretion; (4) absence of edema or volume depletion and (5) normal renal and adrenal function.
A t-test or a w 2 test was used to compare patients with CBSCT and BMT/PBSCT. Statistical analyses were performed using SPSS II for Windows (release 11.0.1J, SPSS Japan Inc.). A P-value of less than 0.05 was regarded as statistically significant.
Results
Syndrome of inappropriate secretion of antidiuretic hormone developed in 25 (12.7%) of the 197 patients who received SCT, and a summary of the backgrounds of the patients with SIADH is provided in (2) and rigidity of limbs (1), but two patients exhibited no symptoms. The median of minimum serum sodium level was 120 mmol/l. The median onset of SIADH was 27 days after SCT and the median number of WBC at the onset of SIADH was 2.3 Â 10 9 /l. Neurological sequelae such as developmental delay and seizure occurred in 5 (20.0%) of the 25 patients with SIADH, whereas in 2 (1.2%) of the 172 patients without SIADH (Po0.01). All patients with neurological sequelae had received allogeneic transplantation. In analysis limited to survivors, neurological sequelae occurred in 5 (23.8%) of the 21 survivors with SIADH, but they occurred in 2 (2.1%) of the 94 survivors without SIADH (Po0.01).
In the patients with SIADH, we compared the abovementioned factors between patients after CBSCT and those after BMT/PBSCT (Table 3) . Age, gender and minimum serum sodium level did not differ between them. However, severe symptoms such as seizure, somnolence and rigidity of limbs were observed in 8 (53.3%) of the 15 patients with CBSCT, but in none of the 10 patients with BMT/PBSCT (Po0.01). Additionally, SIADH developed earlier in patients receiving CBSCT (median onset, 19 days after SCT; range, 15-54 days) than in those receiving BMT/ PBSCT (median onset, 46 days after SCT; range, 18-74 days), and the median numbers of WBC at the onset of SIADH were lower in patients after CBSCT (median, 1.0 Â 10 9 /l; range, 0.1-4.2 Â 10 9 /l) than in those after BMT/PBSCT (median, 3.1 Â 10 9 /l; range, 2.5-13.3 Â 10 9 /l) ( Figure 1 ). These differences were statistically significant (Po0.01). 
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Neurological sequelae occurred in 4 (26.6%) of the 15 patients receiving CBSCT, but in only 1 (10.0%) of the 10 patients after BMT/PBSCT. In analysis limited to survivors, neurological sequelae occurred in 4 (30.8%) of the 13 survivors after CBSCT, whereas it occurred in one (12.5%) of the eight survivors following BMT/PBSCT. These differences were not significant (P40.30).
Discussion
In this study, we revealed for the first time the differences in SIADH clinical features between CBSCT and BMT/ PBSCT treatments; patients receiving CBSCT had an earlier onset, a lower WBC count at the onset, and more severe symptoms than did those receiving BMT/PBSCT, and neurological sequelae were more frequent following SCT in survivors with SIADH than in those without SIADH.
Antineoplastic agents, 5, 6 glucocorticoid, 7 hematological diseases [8] [9] [10] [11] and other factors have been reported to be associated with SIADH. In this study, multivariate analysis revealed that only an alternative donor was independently associated with an increased risk of SIADH, whereas recipient age, gender, primary diseases, acute GVHD or drugs used in the peritransplant period were not independent risk factors (data not shown). These results, except for age, concurred with our previous report. 3 Although we have no available data at present, IL-6 has been reported to be involved in SIADH. [12] [13] [14] In addition, levels of cytokines such as IL-6 and tumor necrosis factor-a are known to be high in SCT from an HLA-mismatched donor or an unrelated donor. 15 These cytokines may induce SIADH following SCT, even though acute GVHD was not associated with the occurrence of SIADH.
In patients with SIADH following SCT, we found different SIADH clinical features following CBSCT and BMT/PBSCT. CsA and methylprednisolone were used more frequently in patients with SIADH following CBSCT, whereas antithymocyte globulin, FK506 and MTX were used more frequently in patients with SIADH following BMT/PBSCT (Po0.04). These drugs, however, were not associated with the occurrence of SIADH. Therefore, these clinical differences are likely due to the difference in the source of stem cells. A major difference in the outcome between CBSCT and BMT/PBSCT is recognized to be that CBSCT needs a longer period for hematological/immunological reconstitution than does BMT/PBSCT. However, the hypothesis that SIADH following SCT treatment is related to the expansion of donor cells is not likely because patients with SIADH following CBSCT had an approximate 3 week earlier onset and one-third of the WBC count at the onset compared to those with SIADH following BMT/PBSCT. The difference in cytokine reactions between CBSCT and BMT/PBSCT, such as pre-engraftment immune reactions proposed as an early phenotype of post-CBSCT immune reaction, 16, 17 may explain these clinical differences.
We have previously shown significantly higher overall and event-free survival rates in patients with SIADH following SCT than those without SIADH. 3 In this study, although this conclusion was confirmed (data not shown), neurological sequelae following SCT occurred in survivors with SIADH more frequently than in those without SIADH. All patients with SIADH were promptly and appropriately treated with fluid restriction, diuretics or hypertonic saline (3% NaCl) and recovered from hyponatremia. NaCl (3%) was given to 23 of the 25 patients and its duration (median, 23 days; range, 1-116 days) was not associated with the source of stem cells or neurological sequelae (data not shown). Patients had no other metabolic disturbances, such as hypocalcaemia, hypomagnesaemia and hyper-or hypoglycemia. Only one patient diagnosed with human herpes virus 6 (HHV-6) encephalitis had a neurological disorder other than SIADH. We therefore speculate that the causes of neurological sequelae are identical to those of SIADH. Although the precise basis for SIADH following SCT still remains unknown, there may be a pattern of cytokines inducing not only SIADH but also a GVL/tumor effect without GVHD. To test this hypothesis, it is important to determine whether there are significant differences in survival rates between malignant and non-malignant diseases. For this purpose, further analysis of a much larger number of patients with SIADH following SCT will be needed. After the onset of SIADH, one patient (case 21) was diagnosed with HHV-6 encephalitis by PCR for HHV-6 using his cerebrospinal fluid. Although he was appropriately treated for SIADH and recovered from hyponatremia, he finally subsequently developed seizures and developmental delay. There are also a few reports of SIADH related to HHV-6 encephalitis. 18, 19 Therefore, we speculate that, in this case, HHV-6 encephalitis caused SIADH and neurological sequelae. SCT often causes many neurological disorders, [20] [21] [22] some of which, such as CNS infections (bacterial and viral), 18, 19, [23] [24] [25] [26] intracranial bleeding and drug toxicity (FK506), 27 have been reported to be associated with SIADH. Thus, subclinical neurological disorders might be present in these patients and elude diagnosis, although we were unable to demonstrate any neurological disorders in other patients with SIADH. Not only cytokine reactions after SCT but also neurological disorders caused by SCT can cause SIADH following SCT and neurological sequelae. SIADH may be considered as a potentially important symptom of neurological disorders and a predictor of neurological sequelae.
In conclusion, we revealed the differences in SIADH clinical features between CBSCT and BMT/PBSCT treatments and the more frequent occurrence of neurological sequelae following SCT in survivors with than without SIADH. The onset of SIADH following SCT was assumed to be associated with cytokine reactions after SCT and/or other neurological disorders caused by SCT. Further analysis of a much larger number of patients with SIADH following SCT is needed to explore the mechanisms of SIADH developing after SCT and to appropriately manage such patients.
